. Author manuscript; available in PMC: 2014 Nov 14.

Published in final edited form as: Recent Pat Nanomed. 2012;2(2):82–95. doi: 10.2174/1877912311202020082

Table 1.

Pharmacokinetic Parameters Following Ocular Administration of 0.1% DEX in Commercial Eye Drops or 0.025% DEX in Micelle Systems Based on F127 or F127 and CH [91].

Ocular Formulations	T_max^a(h)	T_min^b(h)	AUC (% Increase in IOP_t x h)	k_el, app^c (h⁻¹)	AUC_rel^d
F127/DEX in isotonic acetate buffer, pH 4.5 (F1)	1.37±0.21^*	10.15±0.94^*	115.9±8.31^*	0.189±0.05^*	1.72
F127/DEX/0.015 (w/v)% CH in isotonic acetate buffer, pH 4.5 (F4)	1.25±0.23^*	11.23±0.56^*	162.8±11.23^*	0.148±0.05^*	2.41
Commercial DEX (0.1, w/v %) eye drops	2.26±0.14	8.39±0.38	67.6±9.42	0.319±0.06	1

Time needed to achieve peak IOP increase.

Duration of IOP increase response (the time interval needed for the IOP to return to its normal pretreatment value).

Approximate values calculated from the slope ln (% increase in IOP)/Δt for the terminal points of % increase in IOPt versus t curves.

Ratio of AUC to the value for the commercial DEX (0.1, w/v, %) eye drops.

Statistically significant difference as compared with commercial DEX (0.1, w/v, %) eye drops (p < 0.05).